{"id":408511,"date":"2021-01-05T08:33:28","date_gmt":"2021-01-05T13:33:28","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=408511"},"modified":"2021-01-05T08:33:28","modified_gmt":"2021-01-05T13:33:28","slug":"albireo-to-participate-in-h-c-wainwright-bioconnect-and-lifesci-advisors-investor-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/albireo-to-participate-in-h-c-wainwright-bioconnect-and-lifesci-advisors-investor-conferences\/","title":{"rendered":"Albireo to Participate in H.C. Wainwright BioConnect and LifeSci Advisors Investor Conferences"},"content":{"rendered":"
\n

BOSTON, Jan. 05, 2021 (GLOBE NEWSWIRE) — Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, will participate in the H.C. Wainwright Virtual BioConnect 2021 Conference to be held January 11-14, 2021 and the LifeSci Advisors 10th Annual Corporate Access Event to be held January 6-14, 2021.<\/p>\n

The virtual LifeSci Advisors event presentation will be live at 12:00 pm EST on January 8, 2021 from the Albireo Media and Investors page ir.albireopharma.com<\/a> and the H.C. Wainwright fireside chat will be available beginning Monday, January 11, 2021 also at ir.albireopharma.com<\/a>. Both sessions will be archived and available for replay on Albireo\u2019s website for two weeks following the events.\u00a0\u00a0<\/p>\n

\n About Albireo<\/strong>
\n
Albireo Pharma\u00a0is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. Albireo\u2019s lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases with Phase 3 pivotal trials in PFIC, Alagille syndrome and biliary atresia. The Company completed IND-enabling studies for new preclinical candidate A3907 this year and plans to advance development in adult liver disease. Albireo was spun out from AstraZeneca\u00a0in 2008 and is headquartered in\u00a0Boston,\u00a0Massachusetts, with its key operating subsidiary in\u00a0Gothenburg,\u00a0Sweden. The\u00a0Boston Business Journal\u00a0named Albireo one of the 2020 Best Places to Work in\u00a0Massachusetts for the second consecutive year. For more information on Albireo, please visit www.albireopharma.com<\/a>.<\/p>\n

\n Media & Investor contacts:<\/strong>
\n
Colleen Alabiso, 857-356-3905, colleen.alabiso@albireopharma.com<\/a>
Hans Vitzthum, LifeSci Advisors, LLC., 857-272-6177<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

BOSTON, Jan. 05, 2021 (GLOBE NEWSWIRE) — Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, will participate in the H.C. Wainwright Virtual BioConnect 2021 Conference to be held January 11-14, 2021 and the LifeSci Advisors 10th Annual Corporate Access Event to be held January 6-14, 2021. The virtual LifeSci Advisors event presentation will be live at 12:00 pm EST on January 8, 2021 from the Albireo Media and Investors page ir.albireopharma.com and the H.C. Wainwright fireside chat will be available beginning Monday, January 11, 2021 also at ir.albireopharma.com. Both sessions will be archived and available for replay on Albireo\u2019s website for two … <\/p>\n

Continue reading “Albireo to Participate in H.C. Wainwright BioConnect and LifeSci Advisors Investor Conferences”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-408511","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAlbireo to Participate in H.C. Wainwright BioConnect and LifeSci Advisors Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/albireo-to-participate-in-h-c-wainwright-bioconnect-and-lifesci-advisors-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Albireo to Participate in H.C. Wainwright BioConnect and LifeSci Advisors Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BOSTON, Jan. 05, 2021 (GLOBE NEWSWIRE) — Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, will participate in the H.C. Wainwright Virtual BioConnect 2021 Conference to be held January 11-14, 2021 and the LifeSci Advisors 10th Annual Corporate Access Event to be held January 6-14, 2021. The virtual LifeSci Advisors event presentation will be live at 12:00 pm EST on January 8, 2021 from the Albireo Media and Investors page ir.albireopharma.com and the H.C. Wainwright fireside chat will be available beginning Monday, January 11, 2021 also at ir.albireopharma.com. Both sessions will be archived and available for replay on Albireo\u2019s website for two … Continue reading "Albireo to Participate in H.C. Wainwright BioConnect and LifeSci Advisors Investor Conferences"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/albireo-to-participate-in-h-c-wainwright-bioconnect-and-lifesci-advisors-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-05T13:33:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMDMzMSMzOTAzOTk0IzIwODA2NTE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/albireo-to-participate-in-h-c-wainwright-bioconnect-and-lifesci-advisors-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/albireo-to-participate-in-h-c-wainwright-bioconnect-and-lifesci-advisors-investor-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Albireo to Participate in H.C. Wainwright BioConnect and LifeSci Advisors Investor Conferences\",\"datePublished\":\"2021-01-05T13:33:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/albireo-to-participate-in-h-c-wainwright-bioconnect-and-lifesci-advisors-investor-conferences\\\/\"},\"wordCount\":285,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/albireo-to-participate-in-h-c-wainwright-bioconnect-and-lifesci-advisors-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMDMzMSMzOTAzOTk0IzIwODA2NTE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/albireo-to-participate-in-h-c-wainwright-bioconnect-and-lifesci-advisors-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/albireo-to-participate-in-h-c-wainwright-bioconnect-and-lifesci-advisors-investor-conferences\\\/\",\"name\":\"Albireo to Participate in H.C. Wainwright BioConnect and LifeSci Advisors Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/albireo-to-participate-in-h-c-wainwright-bioconnect-and-lifesci-advisors-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/albireo-to-participate-in-h-c-wainwright-bioconnect-and-lifesci-advisors-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMDMzMSMzOTAzOTk0IzIwODA2NTE=\",\"datePublished\":\"2021-01-05T13:33:28+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/albireo-to-participate-in-h-c-wainwright-bioconnect-and-lifesci-advisors-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/albireo-to-participate-in-h-c-wainwright-bioconnect-and-lifesci-advisors-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/albireo-to-participate-in-h-c-wainwright-bioconnect-and-lifesci-advisors-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMDMzMSMzOTAzOTk0IzIwODA2NTE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMDMzMSMzOTAzOTk0IzIwODA2NTE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/albireo-to-participate-in-h-c-wainwright-bioconnect-and-lifesci-advisors-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Albireo to Participate in H.C. Wainwright BioConnect and LifeSci Advisors Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Albireo to Participate in H.C. Wainwright BioConnect and LifeSci Advisors Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/albireo-to-participate-in-h-c-wainwright-bioconnect-and-lifesci-advisors-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Albireo to Participate in H.C. Wainwright BioConnect and LifeSci Advisors Investor Conferences - Market Newsdesk","og_description":"BOSTON, Jan. 05, 2021 (GLOBE NEWSWIRE) — Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, will participate in the H.C. Wainwright Virtual BioConnect 2021 Conference to be held January 11-14, 2021 and the LifeSci Advisors 10th Annual Corporate Access Event to be held January 6-14, 2021. The virtual LifeSci Advisors event presentation will be live at 12:00 pm EST on January 8, 2021 from the Albireo Media and Investors page ir.albireopharma.com and the H.C. Wainwright fireside chat will be available beginning Monday, January 11, 2021 also at ir.albireopharma.com. Both sessions will be archived and available for replay on Albireo\u2019s website for two … Continue reading \"Albireo to Participate in H.C. Wainwright BioConnect and LifeSci Advisors Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/albireo-to-participate-in-h-c-wainwright-bioconnect-and-lifesci-advisors-investor-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-05T13:33:28+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMDMzMSMzOTAzOTk0IzIwODA2NTE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/albireo-to-participate-in-h-c-wainwright-bioconnect-and-lifesci-advisors-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/albireo-to-participate-in-h-c-wainwright-bioconnect-and-lifesci-advisors-investor-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Albireo to Participate in H.C. Wainwright BioConnect and LifeSci Advisors Investor Conferences","datePublished":"2021-01-05T13:33:28+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/albireo-to-participate-in-h-c-wainwright-bioconnect-and-lifesci-advisors-investor-conferences\/"},"wordCount":285,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/albireo-to-participate-in-h-c-wainwright-bioconnect-and-lifesci-advisors-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMDMzMSMzOTAzOTk0IzIwODA2NTE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/albireo-to-participate-in-h-c-wainwright-bioconnect-and-lifesci-advisors-investor-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/albireo-to-participate-in-h-c-wainwright-bioconnect-and-lifesci-advisors-investor-conferences\/","name":"Albireo to Participate in H.C. Wainwright BioConnect and LifeSci Advisors Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/albireo-to-participate-in-h-c-wainwright-bioconnect-and-lifesci-advisors-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/albireo-to-participate-in-h-c-wainwright-bioconnect-and-lifesci-advisors-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMDMzMSMzOTAzOTk0IzIwODA2NTE=","datePublished":"2021-01-05T13:33:28+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/albireo-to-participate-in-h-c-wainwright-bioconnect-and-lifesci-advisors-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/albireo-to-participate-in-h-c-wainwright-bioconnect-and-lifesci-advisors-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/albireo-to-participate-in-h-c-wainwright-bioconnect-and-lifesci-advisors-investor-conferences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMDMzMSMzOTAzOTk0IzIwODA2NTE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMDMzMSMzOTAzOTk0IzIwODA2NTE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/albireo-to-participate-in-h-c-wainwright-bioconnect-and-lifesci-advisors-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Albireo to Participate in H.C. Wainwright BioConnect and LifeSci Advisors Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/408511","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=408511"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/408511\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=408511"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=408511"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=408511"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}